SVMP affecting tumor cells
1. Introduction
Tumorigenesis and metastasis are two processes with inter-related mechanisms. These include tumor growth and angiogenesis, detachment of tumor cells from the primary tumor, followed by migration through the local connective tissue and penetration into the circulation (intravasation). Once in the blood stream, tumor cells interact with circulating blood cells, arrest in the microvasculature of target organs, then extravasate and secondary proliferate. During each of these steps, integrin-mediated adhesion, migration, proliferation and survival of tumor cells and angiogenic endothelial cells play crucial roles [1,2].
Integrins are a family of heterodimeric transmembrane receptors that mediate cell-cell and cell-extracellular matrix (ECM) interactions. These cell adhesion molecules are composed by non covalent association of α and β subunits. Although 18 α and 8 β subunits have been described, only 24 different combinations have been identified to date [3]. Specific integrin heterodimers preferentially bind distinct ECM proteins. The repertory of integrins present on a given cell dictates the extent to which that cell will adhere to and migrate on different matrices. Several integrins, among others αv and α5β1, recognize the RGD sequence on their respective ligands. Other adhesive sequences in ECM proteins have also been observed, including the EILDV and REDV sequences that are recognized by integrin α4β1 in an alternatively spliced form of fibronectin [3]. On ligation to the ECM, integrins cluster in the plane of the membrane and recruit various signalling and adaptor proteins to form structures known as focal adhesions [4].
Integrin expression can also vary considerably between normal and tumor tissue. Most notably, integrins αvβ3, α5β1 and αvβ6 are usually expressed at low or undetectable levels in most adult epithelia but can be highly up-regulated in some tumors. Expression levels of some integrins, such as α2β1, decrease in tumor cells; potentially increasing tumor cell dissemination [5]. The integrin αvβ3 is particularly important for tumor growth and invasiveness [6]. The receptor plays a major role in neo-vessels formation, its expression being strongly up-regulated in endothelial cells and specifically required during angiogenesis stimulated by basic fibroblast growth factor (bFGF) and tumor necrosis factor-α [7,8]. αvβ3 is functionally involved in the malignant spread of various tumor cell types such as breast carcinoma, prostate carcinoma and melanoma, and supports tumor cell adhesion and migration through endothelium [9] and matrix proteins [10,1]. Blocking αvβ3 is therefore expected to have a broad impact in cancer therapy and diagnosis. In the last decade, several clinical trials evaluating the efficacy of αvβ3 blockers have led to encouraging results. Thus, MEDI-522 (Vitaxin), a humanized antibody derived from the mouse LM609 monoclonal antibody, was recently reported to give positive results in a phase II trial enrolling patients with stage IV metastatic melanoma [11]. Cilengitide is an inhibitor of both αvβ3 and αvβ5 integrins; it is currently being tested in phase II trials in patients with lung and prostate cancers [12] and in phase II and Phase III trials studying their role against glioblastoma are currently underway.
In addition to their role in tumor cells, integrins are also important for the host cellular response against cancer. Endothelial cells, fibroblasts, pericytes, bone marrow-derived cells, inflammatory cells and platelets all use integrins for various functions, including angiogenesis, desmoplasia and immune response.
Nature has been a source of medicinal products for thousands of years among which snake venoms form a rich source of bioactive molecules such as peptides, proteins and enzymes with important pharmacological activities. International research and development in this area, based on multidisciplinary approaches including molecular screening, proteomics, genomics and pharmacological
2. Snake venom protein families
2.1. The Snake Venom Metalloproteinases (SVMP)
Metalloproteinases are among the most abundant toxins in many
Most of the functional activities of SVMPs are associated with hemorrhage or the disruption of the hemostatic system, which are primarily mediated by the proteolytic activity of the M domain. SVMPs cause hemorrhage by disturbing the interactions between endothelial cells and the basement membrane through the degradation of endothelial cell membrane proteins (e.g., integrin, cadherin) and basement membrane components (e.g., fibronectin, laminin, nidogen, type IV collagen) [17]. Blood coagulation proteins (e.g., fibrinogen, factor X, prothrombin) are also targets of their proteolytic activities.
In the other side, it was reported that several SVMPs inhibited integrin-mediated adhesion of cancer cells on ECM proteins (table 1). BaG, a dimeric PIII class of SVMP from
VAP1, VAP2 | α3,α6,β1 | Induce apoptosis of HUVEC | [31,36] | |
HV1 | - | Inhibits adhesion of HUVEC and induces apoptosis | [32] | |
Halysase | α1β1;α5β1 | Inhibits proliferation and Induces apoptosis of HUVEC | [33] | |
VLAIPs | - | Inhibits proliferation and Induces apoptosis of HUVEC | [34] | |
Graminelysin | α1β1;α5β1 | Inhibits proliferation and Induces apoptosis of HUVEC | [35] | |
BaG | α5β1 | Inhibits adhesion of K562 cells | [30] | |
TSV-DM | - | Inhibits cell proliferation and induces transient cell morphologic changes of endothelial cells. | [113] |
Several apoptosis-inducing proteins have been purified from hemorrhagic snake venom, such as VAP1 and VAP2 (
2.2. The disintegrins
Disintegrins are a family of non-enzymatic and low molecular weight proteins derived from viper venom [37-39]. They are able to inhibit platelet aggregation and interact with adhesion molecules in particular integrins in a dose-dependent manner. They have a K / RTS sequence which is known as the RGD adhesive loop [37-39]. Their primary structure shows a strong conservation in the arrangement of cysteines [38]. Most disintegrins represent the C-terminal domain of metalloproteinases PIIa, d and e classes and are released into the venom by proteolytic cleavage [40,37,38]. A minority of these proteins exist as D / C domains from the class of SVMPs PIIIb.
Disintegrins can be conveniently divided into five different groups according to their length and the number of disulfide bridges [41]. The first group includes short disintegrins, single polypeptide composed of 49 - 51 amino acids with four disulfide bridges. The second group comprises medium disintegrins containing about 70 amino acids and six disulfide bridges. The third group includes long disintegrins of 83 residues linked by seven disulfide bridges. The disintegrin domains of PIII snake-venom metalloproteinases, containing approx. hundred amino acids with 16 Cysteine residues involved in the formation of eight disulfide bonds, constitute the fourth subgroup of the disintegrin family. Unlike short-, medium- and long-sized disintegrins, which are single-chain molecules, the fifth subgroup is composed of homo and heterodimers. The dimeric disintegrins subunits contain about 67 residues with four disulfide intra-chain bridges and two interchain bridges [42,43].
Although disintegrins are highly homologous, significant differences exist in their affinity and selectivity for integrins, which explains the multitude of effects of these molecules (Table 2).
Disintegrins were first identified as inhibitors of platelet aggregation and were subsequently shown to antagonize fibrinogen binding to platelet integrin αIIbβ3 [44,45]. After that, studies on disintegrins have revealed new uses in the diagnosis of cardiovascular diseases and the design of therapeutic agents in arterial thrombosis, osteoporosis, and angiogenesis-related tumor growth and metastasis (table 2). Triflavin from
Triflavin | α5β1,αvβ3, α3β1 | Inhibits adhesion of tumor cells to matrix proteins, cell migration and angiogenesis | [46] | |
Rhodostomin | αvβ3,αvβ5 | Inhibits cell migration, invasion of endothelial cells; inhibits angiogenesis | [47] | |
Contortrostatin | αvβ3,α5β1, αvβ5, αIIββ3 | Blocks adhesion, migration invasion of different type of tumor cells | [48] | |
Lebestatin | α1β1 | Inhibits migration and angiogenesis | [56] | |
Accurhagin-C | αvβ3 | Prevents migration and invasion of endothelial cells; anti-angiogenic activity | [58] | |
Eristostatin | α4β1,other integrin not yet determined | Inhibits cell motility; no effect on cell proliferation or angiogenesis | [59,60] | |
DisBa-01 | αvβ3 | Anti-angiogenic and anti-metastatic effect on melanoma cells | [62] | |
Leberagin-C | αvβ3 | Inhibits cell adhesion of melanoma tumor cells | [114] | |
Accutin | αvβ3 | Inhibits angiogenesis | [115] |
Contortrostatin, a disintegrin isolated from the venom of the southern copperhead snake, exhibits anti-cancer activity in a variety of tumor cells [48-50]. It does not display cytotoxic activity
Lebestatin is an example of a non toxic KTS-disintegrin isolated from
There are few reports regarding the effects of ECD-disintegrins on endothelial cell migration. Acurhagin-C, dose-dependently blocked HUVEC migration toward a vitronectin-coated membrane. Furthermore, acurhagin-C elicited endothelial anoïkis
Eristostatin, an RGD-disintegrin from
Since integrin receptors are also quite indiscriminate as they support cell adhesion to several substrates, it seems highly reasonable that the general RGD-disintegrin scaffold of the integrin-binding motif could be employed as a prototype for drug design for new anti-metastatic therapies
2.3. The snake venom phospholipases
Snake venom is one of the most abundant sources of secretory phospholipases A2 (PLA2), which are one of the potent molecules in snake venoms [63-65].
PLA2 (EC 3.1.1.4)—are enzymes that catalyze the hydrolysis of sn-2-acyl bond of sn-3-phospholipids, generating free fatty acids and lysophospholipids as products [66]. They are currently classified in 15 groups and many subgroups that include five distinct types of enzymes, namely secreted PLA2 (sPLA2), cytosolic PLA2 (cPLA2), Ca2+ independent PLA2s (iPLA2), platelet-activating factor acetyl-hydrolases (PAF-AH), lysosomal PLA2, and a recently identified adipose-specific PLA2 [65,67]. PLA2 are low molecular weight proteins with molecular masses ranging from 13-19 kDa that generally require Ca2+ for their activities [69,70]. Snake venom sPLA2 are secreted enzymes belonging to only two groups that are based on their primary structure and disulfide bridge pattern [68,71,72]. Those of group I are similar to pancreatic sPLA2 present in mammals, were found in venom of
Despite a high identity of their amino acid sequences, sPLA2 exhibit a wide variety of pharmacological properties such as anticoagulant, haemolytic, neurotoxic, myotoxic, oedema-inducing, hemorrhagic, cytolytic, cardiotoxic, muscarinic inhibitor and antiplatelet activities [63,85-92].
Recently, PLA2s have been shown to possess anti-tumor and anti-angiogenic properties (Table 3). CC-PLA2-1 and CC-PLA2-2 from
CCPLA2-1; CCPLA2-2 | α5β1,αv | Inhibits migration and adhesion of fibrosarcoma and melanoma cells | [93,94] | |
Bth-A-I-PLA2 | - | Anti-tumor activity on adenocarcinoma and leukaemia cells | [95] | |
MVL-PLA2 | α5β1,αv | Inhibits adhesion and migration of human microvascular cells and inhibits angiogenesis | [96] | |
BP II | Prothobotrops flavoviridis | - | Induces cell death in human leukaemia cells | [97] |
MVL-PLA2 is a snake venom phospholipase purified from Macrovipera lebetina venom that inhibited adhesion and migration of human microvascular endothelial cells (HMEC-1) without being cytotoxic. Using MatrigelTM and chick chorioallantoic membrane assays, MVL-PLA2, as well as its catalytically inactivated form, significantly inhibited angiogenesis both
A cell death activity was discovered in Lysine 49-PLA2 called BPII. It induces caspase-independent cell death in human leukaemia cells regardless of its depressed enzymatic activity [97].
2.4. The C-type lectins
The C-type lectins are abundant components of snake venom with various function. Typically, these proteins bind calcium and sugar residues. However, the C-type lectin like proteins from snake venom (termed actually snaclec) does not contain the classic calcium/sugar binding loop and have evolved to bind a wide range of physiologically important proteins and receptors [98].
Snaclecs have a basic heterodimeric structure with two subunits, nearly always linked covalently,
Recently, novel activities of snaclecs were highlighted. They were described for their potential anti-tumor effect by blocking adhesion, migration, proliferation and invasion of different cancer cell lines (Table 4). Among these proteins, EMS16, a heterodimer isolated from the venom of
Lebecetin and lebectin, purified from
Extensive researches have been shown that cell adhesion activities in cancer disease are deregulated. According to this idea, it was also reported that lebectin inhibits these alterations by promoting N-cadherin/catenin complex reorganisation at cell-cell contacts, inducing a strengthening of intercellular adhesion [110].
Another snaclec, BJcuL isolated from
Lebecetin, lebectin | α5β1,αv | Inhibits adhesion, migration and invasion of human tumor cells; inhibits angiogenesis | [106] | |
BJcuL | − | Inhibits tumor cell and endothelial cell growth; induces apoptosis of human gastric carcinoma cells; inhibits cell adhesion and actin cytoskeleton disassembly | [111,112] | |
EM16 | α2β1 | Inhibits adhesion and migration of HUVEC cells | [104] |
3. Potential application of snake venom compounds
Venoms are a rich source of molecules endowed with diverse pharmacological effects. Most part of these molecules act
Until now, no medicine was produced from a native molecule purified from venom. However, several peptidomimetics were designed by basing on the structure of these molecules. The benefits of these peptidomimetics compared to antibodies that can be used for the treatment of certain diseases are: a shorter half-life, reversible inhibition, easier to control a problem and very low immunogenicity. For example, the antihypertensive drug captopril, modelled from the venom of the Brazilian arrowhead viper (
Capoten ® (Captropil) | Angiotensin converted enzyme (ACE) inhibitor/ high blood pressure | Granted FDA approval | |
Integrilin ® (Eptifibatide) | Platelet aggregation inhibitor/acute coronary syndrome | Granted FDA approval | |
Aggrastat ® (tirofiban) | GPIIb-IIIa inhibitor/ myocardial infarct, refractory ischemia | Approved for use with heparin and aspirin for the treatment of acute coronary syndrome | |
Exanta | Thrombin inhibitor/ arterial fibrillation and blood | Seeking FDA approval | |
Alfimeprase | (Agkistrodon contortrix contortrix) | Thrombolytic/ Acute ischemic stroke, acute peripheral arterial occlusion | Phase III |
Ancrod ® (viprinex) | Fibrinogen inhibitor/ stroke | Phase III | |
hemocoagulase | Thrombin-like effect and thromboplastin activity/ prevention and treatment of haemorrhage | Phase III | |
Protac/ Protein C activator | Protein C activator/clinical diagnosis of haemostatic disorder | Granted FDA approval | |
Reptilase | Diagnosis of blood coagulation disorder | Granted FDA approval | |
Ecarin | Prothrombin activator/ diagnostic | Granted FDA approval |
Actually, most of the current anticancer therapies (radiotherapy, chemotherapy) are not specific and are targeting at both tumor cells and healthy cells. However, in recent years, new treatments tend to focus on the tumor microenvironment and particularly on the inhibition of tumor angiogenesis. These treatments are based on several active and non toxic proteins from snake venom, as for example contortrostatin from
4. Conclusions
From the initial discovery of captopril, the first oral ACE inhibitor, to the recent application of disintegrins for the potential treatment of cancer, the various components of snake venoms have never failed to reveal amazing new properties. While the original native snake venom compounds are usually unsuitable as therapeutics, interventions by medicinal chemists as well as scientists and clinicians in pharmaceutical R&D have made it possible to use the snake venom proteins as potential drugs for multiple disorders or scaffolds for drug design.
References
- 1.
Integrin adhesion receptors in tumor metastasis. Clinical and Experimental MetastasisFelding-Habermann B. 2003 20 3 203 213 - 2.
Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Research1975 35 1 218 224 - 3.
Cell Tissue ResearchBarczyk M. Carracedo S. Gullberg D. Integrins 2010 339 1 269 280 - 4.
Berrier AL and Yamada KM. Cell Matrix. Journal of cellular physiology2007 213 3 565 573 - 5.
Increased tumor cell dissemination and cellular senescence in the absence of β1-integrin function. The EMBO JournalKren A. Baeriswyl V. Lehembre F. Wunderlin C. Strittmatter K. Antoniadis H. Fässler R. Cavallaro U. Christofori G. 2007 26 12 2832 2842 - 6.
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer ResearchAlbelda S. M. Mette S. A. Elder D. E. Stewart R. Damjanovich L. Herlyn M. CA Buck 1990 50 20 6757 6764 - 7.
Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science1994 264 5158 569 571 - 8.
Experimental Cell ResearchEnenstein J. Waleh N. S. Kramer R. H. Basic F. G. F. Fbeta T. G. differentially modulate. integrin expression. of human. microvascular endothelial. cells 1992 203 2 499 503 - 9.
Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Molecular Biology of the Cell2001 12 9 2699 2710 - 10.
Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta (3) in prostate cancer progression. Neoplasia2002 4 3 191 194 - 11.
ASCO Annual Meeting Proceedings, Journal of Clinical OncologyHersey P. Sosman J. O’Day S. A. phase I. I. randomized open-label. study evaluating. the antitumor. activity of. M. E. D. I-52 humanized a. monoclonal antibody. directed against. the human. alpha v. beta . (αvβ integrin ±. dacarbazine . D. T. I. C. in patients. with metastatic. melanoma . M. M. A. S. C. 2005 - 12.
Clinical Genitourinary CancerBeekman K. W. Colevas A. D. Cooney K. Dipaola R. Dunn R. L. Gross M. Keller E. T. Pienta K. J. Ryan C. J. Smith D. Hussain M. Phase I. I. evaluations of. cilengitide in. asymptomatic patients. with androgen. independent prostate. cancer scientific. rationale study design. 2006 4 4 299 302 - 13.
Fox JW and Serrano SM. Structural considerations of the snake venom metalloproteinases, key members of the M12 reprolysin family of metalloproteinases, Toxicon2005 45 8 969 985 - 14.
Fox JW and Serrano SM. Insights into and speculations about snake venom metalloproteinase (SVMP) synthesis, folding and disulfide bond formation and their contribution to venom complexity, FEBS Journal2008 275 12 3016 3030 - 15.
Snake venom hemorrhagic and non hemorrhagic metalloendopeptidases, Methods in EnzymolgyTakeya H. Miyata T. Nishino N. Omori-Satoh T. Iwanaga S. 1993 223 365 - 16.
Scientific and standardization committee communications: classification and nomenclature of snake venom C-type lectins and related proteins, Journal of Thrombosis HaemostasisClemetson K. J. Morita T. Manjunatha Kini. R. 2009 360 EOF 360 EOF - 17.
Baramova EN, Shannon JD, Bjarnason JB, Fox JW. Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases. Archives of Biochemistry and Biophysics1989 275 1 63 71 - 18.
Purification and properties of prothrombin activator from the venom of Echis carinatus. Journal of BiochemistryMorita T. Iwanaga S. 1978 83 2 559 570 - 19.
BiochemistryNishida S. Fujita T. Kohno N. Atoda H. Morita T. Takeya H. Kido I. MJ Paine Kawabata. S. Iwanaga S. c. D. N. A. cloning deduced amino. acid sequence. of prothrombin. activator (ecarin. from Kenyan. Echis carinatus. venom 1995 34 5 1771 1778 - 20.
Isolation and characterization of carinactivase, a novel prothrombin activator in Echis carinatus venom with a unique catalytic mechanism. Journal Biological ChemistryYamada D. Sekiya F. Morita T. 1996 271 9 5200 5207 - 21.
Kress LF and Paroski EA. Enzymatic inactivation of human serum proteinase inhibitors by snake venom proteinases. Biochemical and Biophysics Research Communications1978 83 2 649 656 - 22.
Purification and characterization of kaouthiagin, a von Willebrand factor-binding and-cleaving metalloproteinase from Naja kaouthia cobra venom, Thrombosis and HaemostasisHamako J. Matsui T. Nishida S. Nomura S. Fujimura Y. Ito M. Ozeki Y. Titani K. 1998 80 3 499 505 - 23.
Laing GD, Moura-da-Silva AM. Jararhagin and its multiple effects on hemostasis. Toxicon2005 45 8 987 996 - 24.
Kamiguti AS. Platelets as targets of snake venom metalloproteinases. Toxicon2005 45 8 1041 1049 - 25.
Huang TF, Chang MC, Teng CM. Antiplatelet protease, kistomin, selectively cleaves human platelet glycoprotein Ib. Biochemica et Biophysica Acta1993 1158 3 293 299 - 26.
Ward CM, Andrews RK, Smith AI, Berndt MC. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ib alpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ib alpha as a binding site for von Willebrand factor and alpha-thrombin, Biochemistry1996 35 15 4929 4938 - 27.
Wu WB, Peng HC, Huang TF. Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox. Thrombosis and Haemostasis2001 86 6 1501 1511 - 28.
Hsu C. C. Wu W. B. Huang T. F. A. snake venom. metalloproteinase kistomin. cleaves platelet. glycoprotein V. I. impairs platelet. functions Journal. of Thrombosis. Haemostasis 2008 6 9 1578 1585 - 29.
Thrombosis and HaemostasisWijeyewickrema L. C. EE Gardiner Moroi. M. Berndt M. C. Andrews R. K. Snake venom. metalloproteinases crotarhagin. alborhagin induce. ectodomain shedding. of the. platelet collagen. receptor glycoprotein. V. I. 2007 98 6 1285 1290 - 30.
Cominetti MR, Ribeiro JU, Fox JW, Selistre-de-Araujo HS. BaG, a new dimeric metalloproteinase/disintegrin from the Bothrops alternatus snake venom that interacts with alpha5beta1 integrin. Archives of Biochemistry and. Biophysics2003 416 2 171 179 - 31.
Purification of a vascular apoptosis-inducing factor from hemorrhagic snake venom. Biochemical and Biophysics Research CommunicationsMasuda S. Araki S. Kaji K. Hayashi H. 1997 235 1 59 63 - 32.
European Journal of BiochemistryMasuda S. Hayashi H. Atoda H. Morita T. Araki S. Purification c. D. N. A. cloning characterization of. the vascular. apoptosis-inducing protein. H. V. from Trimeresurus. flavoviridis 2001 268 11 3339 3345 - 33.
Journal of BiochemistryYou W. K. Seo H. J. Chung K. H. DS Kim A. novel metalloprotease. from Gloydius. halys venom. induces endothelial. cell apoptosis. through its. protease disintegrin-like domains. 2003 134 5 739 749 - 34.
ToxiconTrummal K. Tonismagi K. Siigur E. Aaspollu A. Lopp A. Sillat T. Saat R. Kasak L. Tammiste I. Kogerman P. Kalkkinen N. Siigu J. A. novel metalloprotease. from Vipera. lebetina venom. induces human. endothelial cell. apoptosis 2005 46 1 46 61 - 35.
Biochemical JournalShin W. U. W. B. Ming-Yi C. C. Tur-Fu L. Purification H. molecular cloning. mechanism of. action of. graminelysin I. a. snake-venom-derived metalloproteinase. that induces. apoptosis of. human endothelial. cells 2001 Pt 3)719 EOF 28 EOF - 36.
Two vascular apoptosis-inducing proteins from snake venom are members of the metalloprotease/disintegrin family. European Journal of BiochemistryMasuda S. Hayashi H. Araki S. 1998 253 1 36 41 - 37.
MA Mc Lane Sanchez. EE Wong A. Paquette-Straub C. Perez J. C. Disintegrins Current. Drugs Targets. Cardiovascular Haematological Disorders. 2004 4 327 - 38.
Calvete JJ. Structure-function correlations of snake venom disintegrins. Current Pharmaceutical Design2005 11 7 829 835 - 39.
ToxiconCalvete J. J. Marcinkiewicz C. Monleon D. Esteve V. Celda B. Juarez P. Sanz L. Snake venom. disintegrins evolution. of structure. function 2005 45 8 1063 1074 - 40.
Structural domains in venom proteins: evidence that metalloproteinases and nonenzymatic platelet aggregation inhibitors (disintegrins) from snake venoms are derived by proteolysis from a common precursor. ToxiconKini R. M. Evans H. J. 1992 30 3 265 293 - 41.
Biochemical JournalCalvete J. J. Moreno-Murciano M. P. Theakston R. D. Kisiel D. G. Marcinkiewicz C. Snake venom. disintegrins novel. dimeric disintegrins. structural diversification. by disulphide. bond engineering. 2003 Pt 3)725 EOF 34 EOF - 42.
Disulphide-bond pattern and molecular modelling of the dimeric disintegrin EMF-10, a potent and selective integrin alpha5beta1 antagonist from Eristocophis macmahoni venom. Biochemical JournalCalvete J. J. Jurgens M. Marcinkiewicz C. Romero A. Schrader M. Niewiarowski S. 2000a Pt 3)573 EOF 81 EOF - 43.
Crystal structure of schistatin, a disintegrin homodimer from saw-scaled viper (Echis carinatus) at 2.5 A° resolution. Journal of Molecular BiologyBilgrami S. Tomar S. Yadav S. Kaur P. Kumar J. Jabeen T. Sharma S. Singh T. P. 2004 341 3 829 837 - 44.
Proceeding of the Society for Experimental Biology and MedicineGould R. J. MA Polokoff Friedman. P. A. Huang T. F. Holt J. C. Cook J. J. Niewiarowski S. Disintegrins a. family of. integrin inhibitory. proteins from. viper venoms. 1990 195 2 168 171 - 45.
ToxiconOuyang C. Yeh H. I. Huang T. F. A. potent platelet. aggregation inhibitor. purified from. Agkistrodon halys. (mamushi snake. venom 1983 21 6 797 804 - 46.
Sheu JR, Yen MH, Kan YC, Hung WC, Chang PT, Luk HN. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(beta3 integrin monoclonal antibody. Biochemica et Biophysica Acta1997 445 EOF 54 EOF - 47.
Yeh CH; Peng HC; Yang RS, Huang TF. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Molecular Pharmacology2001 59 5 1333 1342 - 48.
Pathophysiology of Haemostasis and ThrombosisSwenson S. Costa F. Ernst W. Fujii G. Markland F. S. Contortrostatin a. snake venom. disintegrin with. anti-angiogenic anti-tumor activity. 2005 169 EOF 176 EOF - 49.
Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Molecular Cancer TherapeuticsSwenson S. Costa F. Minea R. Sherwin R. P. Ernst W. Fujii G. Yang D. Markland F. S. Jr 2004 3 4 499 511 - 50.
Cancer ResearchTrikha M. De Clerck Y. A. Markland F. S. Contortrostatin a. snake venom. disintegrin inhibits. beta . integrin-mediated human. metastatic melanoma. cell adhesion. blocks experimental. metastasis 1994 54 18 4993 4998 - 51.
Breast Cancer Research and TreatmentZhou Q. Sherwin R. P. Parrish C. Richters V. Groshen S. G. Tsao-Wei D. Markland F. S. Contortrostatin a. dimeric disintegrin. from Agkistrodon. contortrix contortrix. inhibits breast. cancer progression. 2000a 61 3 249 260 - 52.
Biochemical Biophysical Research CommunicationsZhou Q. Nakada M. T. Brooks P. C. Swenson S. D. Ritter M. R. Argounova S. Arnold C. Markland F. S. Contortrostatin a. homodimeric disintegrin. binds to. integrin alphavbeta. 2000b 267 1 350 355 - 53.
Purification and characterization of platelet aggregation inhibitors from snake venoms. Thrombosis ResearchTrikha M. Rote W. E. Manley P. J. Lucchesi B. R. Markland F. S. 1994 73 1 39 52 - 54.
Journal of Cellular BiochemistryRitter M. R. Zhou Q. Markland F. S. Jr Contortrostatin a. snake venom. disintegrin induces. alphavbeta3-mediated tyrosine. phosphorylation of. C. A. S. in F. A. K. tumor cells. 2000 79 1 28 37 - 55.
The disintegrin contortrostatinin combination with docetaxel is a Potent Inhibitor of Prostate cancer in vitro and in vivo. The ProstateLin E. Wang Q. Swenson S. Jadvar H. Susan G. Ye W. Markland F. Pinski J. 2010 70 12 1359 1370 - 56.
Laboratory InvestigationOlfa K. Z. Jose L. Salma D. Bazaa A. Srairi N. Nicolas A. Maxime L. Zouari R. Mabrouk K. Marvaldi J. Sabatier J. M. El Ayeb M. Marrakchi N. Lebestatin a. disintegrin from. Macrovipera venom. inhibits integrin-mediated. cell adhesion. migration angiogenesis 2005 85 12 1507 1516 - 57.
The presence of the WGD motif in CC8 heterodimeric disintegrin increases its inhibitory effect on alphaII(b)beta3, alpha(v)beta3, and alpha5beta1 integrins. BiochemistryCalvete J. J. Fox J. W. Agelan A. Niewiarowski S. Marcinkiewicz C. 2002 41 6 2014 2021 - 58.
Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis. Experimental Cell ResearchMorris V. L. EE Schmidt Koop. S. Mac Donald. I. C. Grattan M. Khokha R. MA Mc Lane Niewiarowski S. Chambers A. F. Groom A. C. 1995 219 2 571 578 - 59.
Wang WJ. Acurhagin-C, an ECD disintegrin, inhibits integrin alphavbeta3-mediated human endothelial cell functions by inducing apoptosis via caspase-3 activation. British Journal of Pharmacology2010 160 6 1338 1351 - 60.
Sohn YD, Cho KS, Sun SA, Sung HJ, Kwak KW, Hong SY, Kim DS, Chung KH. Suppressive effect and mechanism of saxatilin, a disintegrin from Korean snake (Gloydiussaxatilis), in vascular smooth muscle cells. Toxicon2008 52 3 474 480 - 61.
Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin. ToxiconTian J. Paquette-Straub C. Sage E. H. Funk S. E. Patel V. Galileo D. MA Mc Lane 2007 49 7 899 908 - 62.
Novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clinical & Experimental MetastasisRamos O. H. Kauskot A. Cominetti M. R. Bechyne I. Salla Pontes. C. L. Chareyre F. Manent J. Vassy R. Giovannini M. Legrand C. Selistre-de-Araujo H. S. Crepin M. AA Bonnefoy 2008 25 1 53 64 - 63.
Kini RM. Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes. Toxicon2003 42 8 827 840 - 64.
Burke JE and Dennis EA. Phospholipase A2 Biochemistry. Cardiovascular drugs and Therapy2009a 23 1 1 22 - 65.
Identification and characterization of a phospholipase A2 from the venom of the Saw-scaled viper: Novel bactericidal and membrane damaging activities. BiochimieRamar P. S. Gopalakrishnakone P. Bow H. Puspharaj P. N. Chow V. T. 2010 92 12 1854 1866 - 66.
Biochemica et Biophysica ActaRitonja A. Gubensek F. Ammodytoxin A. a. highly lethal. phospholipase A. from Vipera. ammodytes ammodytes. venom 1985 828 3 93 306 - 67.
ToxiconMaung-Maung T. Gopalakrishnakone P. Yuen R. Tan C. H. A. major lethal. factor of. the venom. of Burmese. Russell’s viper. . Daboia russelli. siamensis isolation N-terminal. sequencing biological activities. of daboiatoxin. 1995 33 1 63 76 - 68.
Haemorrhagic protein of Russell’s viper venom with fibrinolytic and esterolytic activities. ToxiconChakrabarty D. Datta K. Gomes A. Bhattacharyya D. 2000 38 11 1475 1490 - 69.
Kini RM. Phospholipase A2-a complex multifunctional protein puzzle. In: Kini, R M (ed) Enzymes: Structure, Function and Mechanism. John Wiley and Sons, Chichester, England;1997 1 28 - 70.
Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochemica et Biophysica ActaValentin E. Lambeau G. 2000 - 71.
Six DA and Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochemica et Biophysica Acta2000 - 72.
Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity. BiochemistryRouault M. Bollinger J. G. Lazdunski M. Gelb M. H. Lambeau G. 2003 42 39 11494 11503 - 73.
Receptors for a growing family of secreted phospholipases A2. Trends in Pharmacological SciencesLambeau G. Lazdunski M. 1999 20 4 162 170 - 74.
Dennis EA. Phospholipase A2 in ecicosanoid generation. American Journal of Respiratory and Critical Care Medicine2000 Pt 2) S32 S35. - 75.
Angulo Y, Calderon L. An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. ToxiconLomonte B. Angulo Y. Calderon L. 2003 42 8 885 901 - 76.
Tsai IH, Wang YM, Chen YH, Tsai TS. Venom phospholipases A2 of bamboo viper (Trimeresurus stejnegeri): molecular characterization, geographic variations and evidence of multiple ancestries. Biochemical Journal2004 Pt 1)215 EOF 23 EOF - 77.
Biochemica et Biophysica ActaWei J. F. Wei X. L. Chen Q. Y. Huang T. Qiao L. Y. Wang W. Y. Xiong Y. L. He S. H. N. phospholipase A. unique a. subgroup of. snake venom. group I. I. phospholipase A. 2006 1760 3 462 471 - 78.
The primary structure of ammodytin L, a myotoxic phospholipase A2 homologue from Vipera ammodytes venom. European Journal of BiochemistryKrizaj I. Bieber A. L. Ritonja A. Gubensek F. 1991 202 3 1165 1168 - 79.
Biochemical JournalPolgar J. Magnenat E. M. Peitsch M. C. Wells T. N. Clemetson K. J. Asp- is not. an absolute. prerequisite for. the enzymic. activity of. low-M(r phospholipases. A. purification characterization. computer modelling. of an. enzymically active. Ser- phospholipase A. ecarpholin S. from the. venom of. Echis carinatus. sochureki (saw-scaled. viper 1996 Pt 3) 961-968. - 80.
The International Journal of Biochemistry & Cell Biology Cell BiolBao Y. Bu P. Jin L. Wang H. Yang Q. An L. Purification characterization. gene cloning. of a. novel phospholipase. A. from the. venom of. Agkistrodon blomhoffii. ussurensis 2005 37 3 558 565 - 81.
Discovery of novel [Arg49] phospholipase A2 isozymes from Protobothrops elegans venom and regional evolution of Crotalinae snake venom phospholipase A2 isozymes in the southwestern islands of Japan and Taiwan. ToxiconChijiwa T. Tokunaga E. Ikeda R. Terada K. Ogawa T. Oda-Ueda N. Hattori S. Nozaki M. Ohno M. 2006 48 6 672 682 - 82.
Biochemical and biological activities of the venom of the Chinese pitviper Zhaoermia mangshanensis, with the complete amino acid sequence and phylogenetic analysis of a novel Arg49 phospholipase A2 myotoxin. ToxiconMebs D. Kuch U. Coronas F. I. V. Batista C. V. F. Gumprecht A. Possani L. D. 2006 47 7 797 811 - 83.
BiochimieWei J. F. Li T. Wei X. L. Sun Q. Y. Yang F. M. Chen Q. Y. Wang W. Y. Xiong Y. L. He S. H. Purification characterization. cytokine release. function of. a. novel Arg-. phospholipase A. from the. venom of. Protobothrops mucrosquamatus. 2006 88 10 1331 1342 - 84.
Structural and functional roles of the highly conserved active site residue aspartate-49. BiochemistryLi Y. Yu B. Z. Zhu H. Jain M. K. MD Tsai Phospholipase. A. engineering 1994 33 49 14714 14722 - 85.
Kini RM and Evans HJ. Correlation between the enzymatic activity, anticoagulant and antiplatelet effects of phospholipase A2 isoenzymes from Naja nigricollis venom. Thrombosis and Haemostasis1988 60 2 170 173 - 86.
Purification and characterization of a major phospholipase A2 from Russell’s viper (Vipera russelli) venom. ToxiconKasturi S. Gowda T. V. 1989 27 2 229 237 - 87.
The inhibition of clotting complexes of the extrinsic coagulation cascade by the phospholipase A2 isoenzymes from Naja nigricollis venom. Thrombosis ResearchStefansson S. Kini R. M. Evans H. J. 1989 55 4 481 491 - 88.
ToxiconMaung-Maung T. Gopalakrishnakone P. Yuen R. Tan C. H. A. major lethal. factor of. the venom. of Burmese. Russell’s viper. . Daboia russelli. siamensis isolation N-terminal. sequencing biological activities. of daboiatoxin. 1995 33 1 63 76 - 89.
Role of enzymatic activity in the antiplatelet effects of a phospholipase A2 from Ophiophagus hannah snake venom. Life SciencesHuang M. Z. Gopalakrishnakone P. Kini R. M. 1997 61 22 2211 2217 - 90.
Purification and characterization of an organ specific haemorrhagic toxin from Vipera russelli russelli (Russell’s viper) venom. Indian Journal of Biochemistry & BiophysicsKole L. Chakrabarty D. Datta K. Bhattacharyya D. 2000 37 2 114 120 - 91.
Chakrabarty AK, Hall RH, Ghose AC. Purification and characterization of a potent hemolytic toxin with phospholipase A2 activity from the venom of Indian Russell’s viper. Molecular and Cellular Biochemistry2002 - 92.
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. CarcinogenesisDong M. Guda K. Nambiar P. R. Rezaie A. Belinsky G. S. Lambeau G. Giardina C. Rosenberg D. W. 2003 24 2 307 315 - 93.
Two purified and characterized phospholipases A2 from Cerastes cerastes venom that inhibits cancerous cell adhesion and migration. ToxiconZouari-Kessentini R. Luis J. Karray A. Kallech-Ziri O. Srairi-Abid N. Bazaa A. Loret E. Bezzine S. El Ayeb M. Marrakchi N. 2009 53 4 444 453 - 94.
Laboratory InvestigationZouari-Kessentini R. Jebali J. Taboubi S. Srairi-Abid N. Morjen M. Kallech-Ziri O. Bezzine S. Marvaldi J. El Ayeb M. Marrakchi-P N. C. C. A2 L. -P C. C. A2- L. two cerastes. cerastes venom. derived phospholipases. A. inhibit angiogenesis. both in. vitro in vivo. 2010 90 4 510 519 - 95.
Cloning and identification of a complete cDNA coding for a bactericidal and anti-tumoral acidic phospholipase A2 from Bothrops jararacussu venom. Protein JournalRoberto P. G. Kashima S. Marcussi S. Pereira J. O. Astolfi-Filho S. Nomizo A. Giglio J. R. Fontes M. R. Soares A. M. Fança S. C. 2004 23 4 273 285 - 96.
PLoS OneBazaa A. Pasquier E. Defilles C. Limam I. Kessentini-Zouari R. Kallech-Ziri O. El Battari A. Braguer D. El Ayeb M. Marrakchi N. Luis-P J. M. V. L. L. A. snake a. venom phospholipase. A. inhibits angiogenesis. through an. increase in. microtubule dynamics. disorganization of. focal adhesions. P. Lo 2010 e10124 EOF - 97.
Biosciences, Biotechnology and BiochemistryMurakami T. Kamikado N. Fujimoti R. Hamaguchi K. Nakamura H. Chijiwa T. Ohno M. Oda-Ueda A. [. Lys49] phospholipase. A. from Protobothrops. flavoviridis venom. induces caspase-independent. apoptotic cell. death accompanied. by rapid. plasma-membrane rupture. in human. leukemia cells. 2011 75 5 864 870 - 98.
Snake venom C-type lectins interacting with platelet receptors: structure-function relationships and effects on haemostasis. ToxiconLu Q. Navdaev A. Clemetson J. M. Clemetson K. J. 2005 45 8 1089 1098 - 99.
FASEB JournalEble J. A. Niland S. Bracht T. Mormann M. Peter-Katalinic J. Pohlentz G. Stetefeld J. The alpha2beta. integrin-specific antagonist. rhodocetin is. a. cruciform heterotetrameric. molecule F. A. S. E. 2009 23 9 2917 2927 - 100.
Crystal structure of coagulation factor IX-binding protein from habu snake venom at 2.6 A: implication of central loop swapping based on deletion in the linker region. Journal of Molecular BiologyMizuno H. Fujimoto Z. Koizumi M. Kano H. Atoda H. Morita T. 1999 289 1 103 112 - 101.
Crystal structure of EMS16 in complex with the integrin alpha2-I domain. Journal of Molecular BiologyHorii K. Okuda D. Morita T. Mizuno H. 2004 341 2 519 527 - 102.
Crystal structure of von willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibα binding mechanism induced by snake venom proteins. The Journal of Biological ChemistryMaita N. Nishio K. Nishimoto E. Matsui T. Shikamoto Y. Morita T. Sadler J. E. Mizuno H. 2003 278 39 37777 37781 - 103.
BiochemistryRunhua W. R. Manjunatha K. Max C. M. C. Rhodocetin a. novel platelet. aggregation inhibitor. from the. venom of. Calloselasma rhodostoma. . Malayan pit. viper synergistic non covalent. interaction between. subunits 1999 38 23 7584 7593 - 104.
Isolation and characterization of EMS16, a C-lectin type protein from Echis multisquamatus venom, a potent and selective inhibitor of the α2β1 integrin. BiochemistryMarcinkiewicz C. Lobb R. R. MM Marcinkiewicz Daniel. J. L. Smith J. B. Dangelmaier C. Weinreb P. H. Beacham D. A. Niewiarowski S. 2000 39 32 9859 9867 - 105.
Laboratory InvestigationSarray S. Berthet V. Calvete J. J. Secchi J. Marvaldi J. El Ayeb M. Marrakchi N. Luis J. Lebectin a. novel C-type. lectin from. Macrovipera lebetina. venom inhibits. integrin mediated. adhesion migration. invasion of. human tumour. cells 2004 84 5 573 581 - 106.
Matrix BiologySarray S. Delamarre E. Marvaldi J. El Ayeb M. Marrakchi N. Luis J. Lebectin lebecetin two. C-type lectins. from snake. venom inhibit. alpha beta. alpha V-containing. integrins 2007 26 4 306 313 - 107.
Journal of Cellular PhysiologyPilorget A. Conesa M. Sarray S. Michaud-Levesque J. Daoud S. Kim K. S. Demeule M. Marvaldi J. El Ayeb M. Marrakchi N. Beliveau R. Luis J. Lebectin a. Macrovipera lebetina. venom-derived C-type. lectin inhibits. angiogenesis both. in vitro. in vivo. 2007 2007 211 2 307 - 108.
Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. AngiogenesisGolubkov V. Hawes D. Markland F. S. 2003 6 3 213 224 - 109.
Cancer ResearchMarcinkiewicz C. Weinreb P. H. Calvete J. J. Kisiel D. G. Mousa S. A. Tuszynski G. P. Lobb R. R. Obtustatin A. potent selective. inhibitor of. alpha1beta integrin. in vitro. angiogenesis in. vivo 2003 63 9 2020 2023 - 110.
Lebectin increases N-cadherin-mediated adhesion through PI3K/AKT pathway. Cancer LettersSarray S. Siret C. Lehmann M. Marrakchi N. Luis J. El Ayeb M. Andre F. 2009 285 2 174 181 - 111.
The effect of a lectin from the venom of the snake, Bothrops jararacussu, on tumor cell proliferation. Anticancer ResearchPereira-Bittencourt M. Carvalho D. D. Gagliard A. R. Collins D. C. 1999 B)4023 4025 - 112.
BJcuL, a lectin purified from Bothrops jararacussu venom, induces apoptosis in human gastric carcinoma cells accompanied by inhibition of cell adhesion and actin cytoskeleton disassembly. ToxiconNolte S. de Castro Damasio. D. Baréa A. C. Gomes J. Magalhães A. Mello Zischler. L. F. Stuelp-Campelo P. M. Elífio-Esposito S. L. Roque-Barreira M. C. CA Reis-Amaral Moreno. Jcu A. N. B. 2012 59 1 81 85 - 113.
ToxiconWan S. G. Jin Y. Lee W. H. Zhang Y. A. snake venom. metalloproteinase that. inhibited cell. proliferation induced morphological. changes of. E. C. V3 cells 2006 47 4 480 489 - 114.
Matrix BiologyLimam I. Bazaa A. Srairi-Abid N. Taboubi S. Jebali J. Zouari-Kessentini R. Kallech-Ziri O. Mejdoub H. Hammami A. El Ayeb M. Luis J. Marrakchi N. Leberagin-C A. disintegrin-like/cysteine-rich protein. from Macrovipera. lebetina transmediterranea. venom inhibits. alphavbeta integrin-mediated. cell adhesion. 2010 29 2 117 126 - 115.
Biochemica Biophysica ActaYeh C. H. Peng H. C. Yih J. B. Huang T. F. A. new short. chain R. G. D-containing disintegrin. accutin inhibits. the common. pathway of. human platelet. aggregation 1998 1425 3 493 504